A Thieno[3,2-D] pyrimidine class of p110α/GDH1 dual inhibitor SBS-873 suppresses TNBC growth by inhibiting PI3K/mTOR signaling and inducing ferroptosis through glutathione depletion.
BACKGROUND Genetic alterations in phosphoinositide 3-kinase (PI3K) signaling are frequently observed in triple-negative breast cancer (TNBC), with the p110α subunit being the most mutated. Although this identifies p110α as a promising therapeutic target, selective inhibitors have demonstrated limited efficacy. Therefor...